Auris Medical to Present at the JMP Securities Life Sciences Conference on Wednesday, June 22
June 16 2016 - 8:08AM
Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology, today announced that Thomas Meyer,
PhD, Chairman and Chief Executive Officer, will present at the JMP
Securities Life Sciences Conference in New York City on Wednesday,
June 22, 2016, at 2:00 pm EDT. A live webcast of the event will be
available through the Events and Presentations page in the
Investors section of the Auris Medical website at
www.aurismedical.com, and a replay of the presentation will be
available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in otolaryngology. The Company is currently
focusing on the development of treatments for acute inner ear
tinnitus (KeyzilenTM; AM-101) and for acute inner ear hearing loss
(AM-111) by way of intratympanic injection with biocompatible gel
formulations. In addition, Auris Medical is pursuing early-stage
research and development projects. The Company was founded in 2003
and is headquartered in Zug, Switzerland. The shares of the parent
company Auris Medical Holding AG trade on the NASDAQ Global Market
under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
HUG#2021003
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Oct 2023 to Oct 2024